Evaluation on the effect of Ubenimex tablets on the treatment of patients with triple-negative breast cancer undergoing chemotherapy
10.3969/j.issn.1005-1678.2017.05.110
- VernacularTitle:三阴乳腺癌化学治疗中给予乌苯美司片的应用效果评价
- Author:
Qiuyan YU
;
Qixia YU
;
Changying DING
;
Yun ZHU
- Keywords:
triple-negative breast cancer;
chemotherapy;
ubenimex tablets;
lymphocyte
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(5):326-328
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the immune function and the degree of bone marrow suppression of ubenimex tablets on the treatment of patients with triple-negative breast cancer underwent chemotherapy.Methods108 cases in Jiaxing hospital of traditional Chinese medicine were randomly divided into the control group and the experimental group, 54 cases in each group.The two group were all treated with AC-T chemotherapy (pirarubicin+ cyclophosphamide + docetaxel).At this basis, the experimental group were given ubenimex.Flow cytometry was used to detect the changes of T lymphocyte subsets, natural killer cell (NK cell) immune function and peripheral blood cell parameters in the two groups before and after the treatment and 6 months after the treatment.ResultsCompared to the control group, the T lymphocyte subsets and NK cell changes in the experimental group before and after chemotherapy were significantly smaller (P<0.05).The T lymphocyte subsets and NK cells in the experimental group were more accurate than those in the control group (P<0.05).The peripheral blood cells in the experimental group were significantly smaller than those in the control group (P<0.05).Compared with the control group, the whole blood cells increased significantly in the experimental group 6 months after chemotherapy(P<0.05).ConclusionIt can help to reduce the effect of chemotherapeutic drugs on the immune function and bone marrow suppression which ubenimex tablets was used on the treatment patients with triple-negative breast cancer c.Patients can be successfully complete the chemotherapy process, and the long-term and short-term adverse reactions were less, prognosis is good, clinical promotion value is significant.
